The Latest Breaking News from Rigel Pharmaceuticals

Gainers

The Nasdaq Composite dropped by more than 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall…

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Rigel Pharmaceuticals will report an earnings per share (EPS) of $-0.14.

Upgrades For E2open Parent Holdings Inc (NYSE:ETWO), Colliers Securities upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $14.58 and a 52-week-low of $7.66. E2open Parent Holdings closed at $9.37 at the end of the last trading period.

Rigel Pharmaceuticals (NASDAQ:RIGL) brought in sales totaling $20.41 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.06%, resulting in a loss of $22.64 million.

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Rigel Pharmaceuticals will report an earnings per share (EPS) of $-0.13.